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Abstract To date, no studies have investigated the esti-
mated blood loss (EBL) after full robotic low anterior
resection (R-LAR) in a case-matched model, comparing it
with the conventional open approach (O-LAR). Forty-nine
patients in the R-LAR and 105 in the O-LAR group were
matched for age, gender, BMI (body mass index), ASA
(American Society of Anesthesiology) class, tumor–node–
metastasis (TNM) classification and UICC (Union for
International Cancer Control) stage, distance of the lower
edge of the tumor from the anal verge, presence of
comorbidities, and preoperative hemoglobin (Hb). EBL
was significantly higher in the O-LAR group (P \ 0.001);
twelve units of packed red blood cells were globally
transfused in the O-LAR group, compared to one unit only
in the R-LAR (P = 0.051). A significantly higher postop-
erative Hb drop (3.0 vs. 2.4 g/dL, P = 0.015) was regis-
tered in the O-LAR patients. The length of hospital stay
was much lower for the R-LAR group (8.4 vs. 12.4 days,
P \ 0.001). The number of harvested lymph nodes (17.4
vs. 13.5, P = 0.006) and extent of distal margin (2.9 vs.
1.9 cm, P \ 0.001) were significantly higher in the R-LAR
group. Open surgery was confirmed as the sole variable
significantly associated (P \ 0.001) with blood loss (odds
ratio = 4.41, 95% CI 2.06–9.43). It was a confirmed
prognosticator of blood loss (P = 0.006) when a preoper-
ative clinical predictive model was built, using multivariate
analysis (odds ratio = 3.95, 95% CI 1.47–10.6). In con-
clusion, R-LAR produced less operative blood loss and less
drop in postoperative hemoglobin when compared to
O-LAR. Other clinically relevant outcomes were similar or
superior to O-LAR.
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Introduction
Precise robotic movements and fine manipulation of tissues
in a close and fixed operating field make rectal cancer
surgery an important application of robotic surgery, and in
fact robot-assisted low-anterior resection (R-LAR)—with
either total or tumor-specific mesorectal excision (TME)—
was reported by several authors as a technically feasible
and oncologically safe procedure for treatment of rectal
cancer [1–5]. As robotic views of the operating field during
R-LAR procedures require a relatively bloodless field,
R-LAR might be expected to lead to less operative blood
loss than open conventional low anterior resection
(O-LAR). This has some interest for clinicians, as it has
been reported that allogenic blood transfusion might be
associated with an increased risk of tumor recurrence after
colorectal cancer surgery [6, 7]. Studies of blood loss after
O-LAR have had variable results, with rates of periopera-
tive transfusions ranging from 20 to 75% [8]. To date,
some studies have reported estimated blood loss (EBL)
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after R-LAR [9, 10], but no study has investigated this
topic as a case-matched model, comparing open and
robotic approaches. This study compares blood loss as
measured by EBL, mean drop in hemoglobin levels with
surgery, and blood product use in patients undergoing O-
LAR or R-LAR in different periods of time at the same
institution, maintaining the same guidelines for transfusion
in the postoperative period. In addition, some clinically
relevant data on early outcomes were investigated.
Methods
All patients undergoing R-LAR or O-LAR in this study
were entered into a prospectively-managed database, along
with their age, sex, diagnosis received (including patho-
logic stage), and data regarding preoperative chemo-radi-
ation therapy performed, if any. Only tumors with the distal
edge within 12 cm of the anal verge were considered for
this study. Operative details included operating time,
American Society of Anesthesiologists (ASA) class, body
mass index (BMI), EBL, and complications, including
readmission within 30 days of hospital discharge.
Standard surgical techniques—emphasizing the need for
TME—were routinely applied during this study, as previ-
ously published elsewhere [4, 11]. A da Vinci STM surgical
robot was always used for this study (Intuitive Surgical,
Sunnyvale, CA). Surgical specimens were routinely dis-
sected by experienced pathologists not aware of the sur-
gical technique used. Pathologic examination included
disease tumor–node–metastasis (TNM) stage, number of
lymph nodes harvested, and longitudinal and radial mar-
gins of resection using standard techniques; in some cases,
depending on the pathologist’s judgement, clearing fixa-
tives were used prior to the dissection.
Consecutive unselected patients undergoing R-LAR
between January 2007 and December 2009 were matched
with patients undergoing O-LAR in the same institution
during a previous 3-year period—between January 2004
and December 2006—for age, gender, ASA class and
comorbidity as denoted by the hospital coding system
(Diagnosis Related Grouping). In the O-LAR group, only
patients without a history of major laparotomy (except
cholecystectomy, appendectomy, or gynecologic surgery
by a lower abdomen incision) were considered for com-
parison with the R-LAR group. Preoperative values for
hemoglobin level and the corresponding postoperative
values taken routinely on the first and third day after sur-
gery were gathered by reviewing the central laboratory
computer software system, into which all laboratory results
were routinely entered. In this way, the mean drop in
hemoglobin levels with surgery was registered.
EBL was regularly recorded on the patient’s chart at the
end of the surgical procedure by the anesthesiologist and
scrub nurse; drainage containers, and number of sponges
and gauze pads used were carefully assessed.
The number of units of blood transfused on the day of
surgery, during the first 48 h after surgery, and for the
duration of the patient’s hospital stay were determined
from the central laboratory computer software system, and
cross-checked with data contained in the patient’s cards.
The recommended standard transfusion trigger for the
institution is to give red blood packed cells to patients with
a Hb level lower than 7 g/dL, unless the patient has a
history of cardiac disease or there is active bleeding. This
policy did not change during the entire 6-year period of the
study, between January 2004 and December 2009.
Data on postoperative course and complications were
reported on hospital cards by the surgical team. In addition,
an epidemiology nurse was in charge to regularly collect
microbiology data with respect to nosocomial infections
(surgical site infections, pneumonias, urine, and intravas-
cular catheters).
All complications were registered, with the exception of
those considered as deviations from the normal postoper-
ative course without the need for pharmacologic treatment
or surgical, endoscopic, and radiologic interventions,
according to the classification method proposed by Clavien
et al. [12].
Hospital discharge was subjected to pre-defined condi-
tions, in agreement with institutional policy, including fully
resumed oral feeding, recovered intestinal function, auton-
omous walking, and approval of responsible physician.
Statistical analysis
Summary statistics (counts, percentages, mean, median,
standard deviation, min and max) for patients’ character-
istics, pathologic findings and clinically relevant post-
operative outcomes except blood loss were tabulated
according to surgery type. Blood loss was summarized
using mean, median, 5th and 95th percentiles, and box-
plotted against type of surgery. Categorical variables were
compared using Fisher’s exact test or the chi-square test.
After checking the normality assumption (Kolmogorov–
Smirnov test), continuous variables were compared using
either the Wilcoxon two-sample test or the unpaired t-test
as appropriate. Univariate and multivariate odds ratios with
95% confidence intervals were estimated in a logistic
regression model after removing collinear predictors. All
tests were considered statistically significant at a= 0.05 and
two-sided. All analyses were conducted using SAS 9.2
software (Cary, NC, USA).
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Results
Forty-nine patients in the R-LAR and 105 in the O-LAR
group could be fully matched for age, gender, BMI, TNM
classification, and UICC (Union for International Cancer
Control) stage, distance of the lower edge of the tumor
from the anal verge, presence of comorbidities, and pre-
operative Hb. No patients received preoperative transfu-
sions, as Hb values were found normal in all patients. ASA
class III patients were significantly more prevalent in the
open-surgery group, whereas the percentage of patients
who underwent neoadjuvant preoperative chemo-radiation
therapy was significantly higher in the robotic surgery
group (Table 1).
EBL was significantly higher in the O-LAR group
(P \ 0.001); 75% of R-LAR patients did not experienced
any clinically significant intraoperative blood loss, com-
pared to 41% of the O-LAR group (P = 0.001), as shown
in Table 2 and Fig. 1. Neither intraoperative transfusions
nor deaths were observed in these series (Table 3). Six
patients in the O-RAR and only one in the R-LAR group
received transfusions in the postoperative period
(P = 0.432); twelve units of packed red blood cells were
transfused in the O-LAR group compared to one unit in the
R-LAR patients (P = 0.051). A significantly higher post-
operative Hb drop (3.0 vs. 2.4 g/dL, P = 0.015) was reg-
istered in the O-LAR patients; postoperative complication
rates did not differ significantly between the matched
Table 1 Characteristics of the
matched patients who
underwent low anterior rectal
resection by the open and
robotic approaches
* Two-sample two-sided
Wilcoxon test, unpaired t test,
chi-square or two-sided Fisher’s
exact test as appropriate
Characteristic Open-LAR Robotic-LAR P value*
Continuous variables Mean ± SD Mean ± SD
Age (years) 61.6 ± 11.7 59.5 ± 11.3 0.414
BMI 24.9 ± 3.6 24.9 ± 4.0 0.956
Distance from the anal verge (cm) 7.9 ± 3.4 6.9 ± 2.6 0.091
Preoperative Hb (g/dL) 13.5 ± 1.5 13.3 ± 1.5 0.392
Categorical variables N (%) N (%)
Sex
Female 42 (40.0) 22 (44.9) 0.601
Male 63 (60.0) 27 (55.1)
ASA class
I 13 (12.5) 9 (18.4)
II 51 (49.0) 38 (77.6) \0.001
III 40 (38.5) 2 (4.1)
Tumor stage (TNM)
T0 15 (14.3) 10 (20.8) 0.843
T1 9 (8.6) 3 (6.3)
T2 31 (29.5)
T3 47 (44.8) 20 (41.7)
T4 3 (2.9) 2 (4.2)
Node stage (TNM)
N0 65 (61.9) 30 (62.5) 0.878
1 31 (29.5) 15 (31.2)
2 9 (8.6) 3 (6.3)
Metastases stage (TNM)
M0 98 (93.3) 42 (91.3) 0.659
1 7 (6.7) 4 (8.7)
UICC Stage
I 23 (21.9) 12 (24.5)
II 40 (38.1) 19 (38.8) 0.979
III 35 (33.3) 15 (30.6)
IV 7 (6.7) 3 (6.1)
Neoadjuvant preop CT/RT 55 (52.4) 36 (73.5) 0.013
Presence of comorbidities 40 (38.1) 21 (42.9) 0.574
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groups, either for infectious or non-infectious complica-
tions. No patients in the R-LAR group experienced a
conversion to laparotomy; two patients needed another
operation, but bleeding was not the cause. Finally, the
length of hospital stay was much lower for the R-LAR
group (8.4 vs. 12.4 days, P \ 0.001). With respect to rel-
evant pathologic findings, radial circumferential margins
did not differ significantly between the groups (about 100%
of free margin for both), whereas number of harvested
lymphnodes (17.4 vs. 13.5, P = 0.006) and extent of distal
margin (2.9 vs. 1.9 cm, P \ 0.001) were significantly more
favorable in the robotic group (Table 4).
Univariate analysis of blood-loss risk estimates was
performed, taking into consideration a number of possible
variables (Table 5). Only open surgery was confirmed to be
significantly associated (P \ 0.001) with blood loss during
the hospital stay (odds ratio = 4.41, 95% CI 2.06–9.43,
compared with referenced robotic surgery). Open surgery
was again confirmed as the only prognosticator of blood
loss (P = 0.006) when a preoperative clinical predictive
model was built, using a multivariate analysis of blood-loss
risk estimate (odds ratio = 3.95, 95% CI 1.47–10.6, com-
pared with referenced robotic surgery) (Table 6).
Discussion
Previous studies have already supported the feasibility and
oncologic safety of robotic LAR, although their results
were limited by the small number of cases representing the
early phase of the learning curve [13]. Since the first
reports of robot-assisted rectal cancer surgery, the advan-
tages of the robotic approach were focused on better early
postoperative outcomes compared with conventional open
analogue procedures, including earlier recovery, less
postoperative pain due to smaller incisions, and a shorter
postoperative hospital stay [14]. Blood loss has not been
investigated in depth until now, in spite of immunosup-
pression, an untoward effect of allogenic transfusion,
which has been postulated to result in decreased tumor
surveillance and detrimental outcome. In 1982, Burrows
and Tartter first linked perioperative allogenic blood
Table 2 Estimated blood loss in the open and robotic groups
Blood loss Open-LAR Robotic-
LAR
P value*
None, N (%) 42 (41.2) 36 (75.0) \0.001
Mean (5th, 95th percentiles) 146.4 (0, 500) 83.7 (0, 500) 0.001
Median 100 0
Min, max 0, 2000 0, 1500
* Fisher’s two-sided test or Wilcoxon test as appropriate
Fig. 1 Box-plots of estimated blood loss in the open and robotic
groups
Table 3 Clinically relevant
outcomes
* Two-sample two-sided
Wilcoxon test, unpaired t test,
chi-square or two-sided Fisher’s
exact test as appropriate
Outcome Open-LAR Robotic-LAR P value*
Intraoperative transfusions 0 0 –
Death 0 0 –
Postoperative transfusions
Patients, N (%) 6 (5.7) 1 (2.0) 0.432
Units, N 12 1 0.051
Surgical complications (30th postoperative day)
Infectious 15 (14.3) 8 (16.3) 0.189
Non-infectious 11 (10.5) 10 (20.4)
Both 5 (4.5) 0
Overall 31 (29.5) 18 (36.7) 0.371
Reinterventions (30th postoperative day) 0 2 (4.1) 0.100
Length of hospital stay (days) mean ± SD (median) 12.4 ± 3.2 (12.0) 8.4 ± 9.3 (7.0) \0.001
Post-operative Hb (g/dL) mean ± SD (median) 10.6 ± 1.6 (10.8) 11.0 ± 1.4 (10.8) 0.124
Hb drop (g/dL) mean ± SD (median) 3.0 ± 1.4 (2.9) 2.4 ± 1.6 (2.0) 0.015
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transfusion to the prognosis of colorectal malignancy [15].
More recently (2006), a Cochrane Collaboration Review
[16] confirmed in an updated meta-analysis the hypothesis
that perioperative blood transfusions have a detrimental
effect on the recurrence of curable colorectal cancers; the
authors concluded that carefully restricted indications for
allogenic blood transfusion are necessary in this clinical
setting, although a causal relationship cannot be claimed,
due to the heterogeneity detected and the not yet com-
pletely defined impact of surgical technique [17].
To date, there is no uniform consensus on the relative
blood loss when patients undergo low anterior resection for
cancer using an open or a robotic approach, and that is true
also for laparoscopic low anterior resection. While some
studies found that EBL during minimally invasive colo-
rectal resections was significantly lower than during ana-
logue open procedures [18–21], others found the loss to be
comparable [22, 23]. A possible reason could be the fact
that most of these studies used EBL as the sole measure of
blood loss during surgery, a parameter previously reported
to be an inconsistent estimate of real blood loss [24, 25]. We
used two additional measures to precisely define the blood
loss related to surgery: postoperative hemoglobin level drop
and overall use of blood products. Hemoglobin drop was
much less in the robotic group, thus confirming a significant
superiority of robot-assisted LAR in this clinical setting,
whereas overall use of blood products showed a trend in
favor of the R-LAR patients (12 vs. 1 units of packed red
blood cells, P = 0.051). In both univariate and multivariate
analyses, conventional open surgery was confirmed as the
sole variable significantly associated with blood loss;
moreover, it was confirmed as a prognosticator of blood loss
when a preoperative clinical predictive model was built.
Interestingly, oncology outcomes were also in favor of
the robotic group, as witnessed by a higher number of
harvested lymph nodes and a higher extent of free distal
margin in the surgical specimens, thus confirming previous
observations of our and other groups [13]. These results
have been obtained while maintaining a comparable rate of
surgical peroperative complications and a much lower
hospital stay in the R-LAR group.
There are several limitations of this study that deserve
some mentions. First, this is not a randomized trial, and
therefore it could suffer from the typical limitations of
observational-descriptive studies. Nevertheless, this is the
first study specifically addressing the topic of blood loss
and use of blood products in robotic low anterior resection,
by means of a comparison between two quite large series of
case-matched patients undergoing the same oncology pro-
cedure (low anterior resection) by the same surgical team,
using a conventional open and a full robotic approach in
the same institution and in a consecutive period of 6 years
(three per group). During this study period, practice of care,
perioperative management, and, in particular, transfusional
policies did not change in our institution.
Another point to be noted is matching, since a poten-
tially important difference between the groups was the
higher prevalence of ASA class 3 in the open surgery one.
This could reflect possible changes in the attitude and
judging of attending anesthesiologists, to whom patients’
ASA classification is routinely given, as the anesthesiology
team differed during the study periods, unlike the surgical
one. However, our multivariate analysis is adjusted for all
patients and tumor characteristics of prognostic relevance,
and it excluded ASA class as a variable possibly associated
with blood loss.
The higher prevalence in the robotic arm of patients who
underwent preoperative neoadjuvant treatment (73.5% vs.
52,4%, P = 0.013) is worth of further comment. Use of
preoperative neoadjuvant chemo-radiation therapy became
a standard option in our institution for locally advanced
disease, preoperatively staged as any T, N positive
or C T3, any N, and this explains the higher prevalence of
these cases in the second group (R-LAR), treated since
2007. A large previous trial, using a conventional open
approach, reported that patients randomly assigned to
preoperative radiation therapy lost more blood than those
assigned to surgery alone (median blood loss 1,000 vs.
900 mL; P \ 0.001) [26]. Our data do not confirm these
results: firstly, no differences were detected between pre-
operative chemo-radiation and immediate surgery groups
in terms of EBL; moreover, median EBL for open surgery
was only 100 mL, and zero mL for the robotic group.
These findings probably reflect a significant and general
improvement in surgical techniques, since these reference
surgical data come from a national study concluded in the
late 1990s; moreover, they underline the superiority of the
robotic technique applied to LAR also in ‘‘difficult’’
Table 4 Pathological findings
* Two-sample two-sided
Wilcoxon test, unpaired t test,
chi-square or two-sided Fisher’s
exact test as appropriate
Parameter Open-LAR Robotic-LAR P value*
Radial margin (cm), N (%)
Negative 103 (98.1) 49 (100) 1.000
Positive 2 (1.9) 0
Harvested lymphnodes, mean ± SD 13.5 ± 6.7 17.4 ± 8.7 0.006
Distal margin (cm), mean ± SD (median) 1.9 ± 1.2 (1.8) 2.9 ± 1.6 (2.6) \0.001
J Robotic Surg (2011) 5:101–107 105
123
patients, such as those who underwent chemo-radiation
neoadjuvant treatment. With respect to this issue, it is
noteworthy to point out that we always applied—in both
groups—one or more sheets of regenerated oxidized cel-
lulose (Tabotamp or Tabotamp Fibrillar, Johnson &
Johnson, Pratica di Mare, Rome, Italy) in case of residual
bleeding after mesorectal excision, usually coming from
small sacral and coccygeal interrupted venules. This is a
Table 5 Univariate blood-loss risk estimates
Risk factor Odds ratio (95% CI) P value*
Surgery
Robotic Reference
Open 4.41 (2.06, 9.43) \0.001
Sex
Male Reference
Female 0.54 (0.28, 1.04) 0.067
Age (years)
B62a Reference
[62 0.74 (0.39, 1.41) 0.360
BMI
B25a Reference
[25 1.65 (0.87, 3.15) 0.125
Distance anal verge (cm)
B7a Reference
[7 0.64 (0.34, 1.23) 0.183
Surgery time (min)
B223a Reference
[223 0.78 (0.40, 1.50) 0.448
Lymph nodes
B14a Reference
[14 0.54 (0.29, 1.05) 0.068
Ostomy
No Reference
Yes 0.61 (0.32, 1.16) 0.132
ASA
I Reference
II 1.46 (0.56, 3.83) 0.443
III 2.52 (0.86, 7.39) 0.093
Neoadjuvant CT/RT
No Reference
Yes 0.90 (0.47, 1.73) 0.762
UICC Stage
I Reference
II 0.63 (0.27, 1.49) 0.291
III 0.47 (0.19.1.13) 0.092
IV 0.70 (0.17, 2.88) 0.621
TNM
T0–T1 Reference
T2 1.33 (0.50, 3.58) 0.568
T3–T4 0.60 (0.24, 1.52) 0.280
Comorbidities
No Reference
Yes 0.58 (0.30, 1.12) 0.106
a Median value
* Two-sample two-sided Wilcoxon test, unpaired t test, chi-square or
two-sided Fisher’s exact test as appropriate
Table 6 Multivariate blood-loss risk estimates—pre-operative clini-
cal predictive model
Risk factor Odds ratio (95% CI) P value
Surgery
Robotic Reference
Open 3.95 (1.47, 10.6) 0.006
Sex
Male Reference
Female 0.57 (0.25, 1.30) 0.179
Age (years)
B62 Reference
[62 0.55 (0.25, 1.23) 0.147
BMI
B25a Reference
[25 1.29 (0.60, 2.79) 0.513
Distance from anal verge (cm)
B7a Reference
[7 0.50 (0.19, 1.26) 0.136
Surgery time (min)
B223a Reference
[223 1.18 (0.48, 2.93) 0.712
ASA
I Reference
II 1.45 (0.47, 4.42) 0.518
III 2.02 (0.55, 7.46) 0.292
Neoadjuvant CT/RT
No Reference
Yes 0.78 (0.32, 2.27) 0.596
UICC Stage
I Reference
II 0.56 (0.20, 1.57) 0.273
III 0.42 (0.14.1.26) 0.120
IV 0.67 (0.14, 3.20) 0.618
a Median value
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fairly common finding in pretreated rectal cancer patients,
where the presacral Waldayer’s fascia is frequently
involved in a thick, fibrous post-radiation tissue, and sacro-
coccygeal venules cannot be easily identified.
In conclusion, this study specifically evaluated whether
robotic LAR reduces estimated intraoperative blood loss,
postoperative Hb drop, and use of blood products when
compared with carefully matched open LAR cases. Robotic
LAR was found to lead to significantly less operative blood
loss and less postoperative Hb drop, together with much
lower use of blood products (P = 0.051) in these patients.
Other clinically relevant outcomes—like length of hospital
stay and pathologic findings—were found similar or
superior to open LAR.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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